LGG-22. SJ901: Phase I/II evaluation of single agent mirdametinib (PD-0325901), a brain-penetrant MEK1/2 inhibitor, for the treatment of children, adolescents, and young adults with low-grade glioma (LGG)

BACKGROUND: MEK inhibitor trials in pediatric low-grade glioma (pLGG) have yielded promising results, but there remains room for improvement since objective responses are rarely complete and disease recurrence after completion of therapy is common. Mirdametinib (PD-0325901) is a highly selective MEK...

Descripción completa

Detalles Bibliográficos
Autores principales: Vinitsky, Anna, Chiang, Jason, Bag, Asim K, Campagne, Olivia, Stewart, Clinton F, Dunphy, Paige, Shulkin, Barry, Li, Qian, Lin, Tong, Hoehn, Mary Ellen, Johnson, Jason N, Towbin, Jeffrey A, Khan, Raja, Tatevossian, Ruth G, Armstrong, Gregory T, Potter, Brian, Conklin, Heather, Shearer, Todd, Scott, Susan, Robinson, Giles W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Low Grade Glioma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164943/
http://dx.doi.org/10.1093/neuonc/noac079.336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164943/
http://dx.doi.org/10.1093/neuonc/noac079.336

Ejemplares similares